A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Advanced and/or Metastatic Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 14 Oct 2015
At a glance
- Drugs XL 413 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 10 Jun 2017 Biomarkers information updated
- 11 Aug 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 01 May 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.